{
    "Clinical Trial ID": "NCT00932373",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Trastuzumab-MCC-DM1 0.3 mg/kg Every 3 Weeks",
        "  Trastuzumab-MCC-DM1 0.3 mg/kg administered intravenously (IV) once every 3 weeks",
        "INTERVENTION 2: ",
        "  Trastuzumab-MCC-DM1 0.6 mg/kg Every 3 Weeks",
        "  Trastuzumab-MCC-DM1 0.6 mg/kg administered intravenously (IV) once every 3 weeks"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically documented, incurable, locally advanced or metastatic breast cancer",
        "  Evaluable or measurable HER2-positive disease",
        "  History of progression during or within 60 days after treatment with any prior trastuzumab-containing chemotherapy regimen for HER2-positive breast cancer",
        "  Previous treatment with chemotherapy for MBC",
        "  Granulocyte count  1,500/\u03bcL, platelet count  100,000/\u03bcL, and hemoglobin  9 g/dL",
        "  Serum bilirubin  1.5 mg/dL; AST, ALT, and alkaline phosphatase  2.5 \u00d7 upper limit of normal (ULN) except for: Patients with hepatic metastases: ALT and AST  5 \u00d7 ULN Patients with hepatic and/or bone metastases: alkaline phosphatase  5 \u00d7 ULN",
        "  Serum creatinine  1.5 mg/dL or creatinine clearance of  60 mL/min based on a 24-hour urine collection",
        "  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2",
        "  Women of childbearing potential and men must agree to use an effective method of birth control (e.g., hormonal, barrier) while receiving study treatment",
        "Exclusion Criteria:",
        "  History of significant cardiac disease, unstable angina, CHF, myocardial infarction, or ventricular arrhythmia requiring medication",
        "  History of Grade  3 hypersensitivity reaction to trastuzumab",
        "  History of any toxicity to trastuzumab that resulted in trastuzumab being permanently discontinued",
        "  Symptomatic brain metastases or any radiation or surgery for brain metastases within 3 months of first study treatment",
        "  Require supplemental oxygen for daily activities",
        "  Grade  2 peripheral neuropathy",
        "  Bisphosphonate therapy for symptomatic hypercalcemia",
        "  Any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biologic therapy for the treatment of breast cancer within 4 weeks of first study treatment",
        "  Any experimental therapy within 4 weeks of first study treatment",
        "  Any major surgical procedure within 4 weeks of first study treatment",
        "  History of clinically symptomatic liver disease, including viral or other hepatitis, current or history of alcoholism, or cirrhosis",
        "  Pregnancy or lactation",
        "  Cardiac troponin I  0.2 ng/mL",
        "  Ejection fraction < 50% or below the lower limit of normal determined by echocardiogram or MUGA scan",
        "  Prior cumulative doxorubicin dose of > 360 mg/m2 or equivalent"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Percentage of Participants With Adverse Events (AE), Serious Adverse Events (SAE), AEs With Grade >=3, and AEs Related To Treatment",
        "  The time frame for AEs is study treatment initiation until 30 days after last administration of study treatment or at the time of initiation of another anti-cancer therapy, which ever occurs first.",
        "  The time frame for SAEs is study treatment initiation until 90 days after last administration of study treatment or at the time of initiation of another anti-cancer therapy, which ever occurs first.",
        "  Time frame: Study treatment initiation until 30 or 90 days after last administration of study treatment",
        "Results 1: ",
        "  Arm/Group Title: Trastuzumab-MCC-DM1 0.3 mg/kg Every 3 Weeks",
        "  Arm/Group Description: Trastuzumab-MCC-DM1 0.3 mg/kg administered intravenously (IV) once every 3 weeks",
        "  Overall Number of Participants Analyzed: 3",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  At least 1 AE: 100",
        "AEs with Grade >=3: 33.3",
        "  At least 1 SAE: 33.3",
        "  AEs related to treatment: 66.7",
        "Results 2: ",
        "  Arm/Group Title: Trastuzumab-MCC-DM1 0.6 mg/kg Every 3 Weeks",
        "  Arm/Group Description: Trastuzumab-MCC-DM1 0.6 mg/kg administered intravenously (IV) once every 3 weeks",
        "  Overall Number of Participants Analyzed: 1",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  At least 1 AE: 100",
        "AEs with Grade >=3: 100",
        "  At least 1 SAE: 100",
        "  AEs related to treatment: 100"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1/3 (33.33%)",
        "  Pain 0/3 (0.00%)",
        "  Cellulitis 0/3 (0.00%)",
        "  Influenza 0/3 (0.00%)",
        "  Osteomyelitis 0/3 (0.00%)",
        "  Pneumonia 0/3 (0.00%)",
        "  Humerus Fracture 0/3 (0.00%)",
        "  Brain Oedema 0/3 (0.00%)",
        "  Cerebral Haemorrhage 0/3 (0.00%)",
        "  Convulsion 0/3 (0.00%)",
        "  Dysarthria 0/3 (0.00%)",
        "  Hepatic Encephalopathy 0/3 (0.00%)",
        "  Confusional State 0/3 (0.00%)",
        "  Dyspnoea 1/3 (33.33%)",
        "Adverse Events 2:",
        "  Total: 1/1 (100.00%)",
        "  Pain 0/1 (0.00%)",
        "  Cellulitis 0/1 (0.00%)",
        "  Influenza 0/1 (0.00%)",
        "  Osteomyelitis 0/1 (0.00%)",
        "  Pneumonia 0/1 (0.00%)",
        "  Humerus Fracture 0/1 (0.00%)",
        "  Brain Oedema 0/1 (0.00%)",
        "  Cerebral Haemorrhage 0/1 (0.00%)",
        "  Convulsion 0/1 (0.00%)",
        "  Dysarthria 0/1 (0.00%)",
        "  Hepatic Encephalopathy 0/1 (0.00%)",
        "  Confusional State 0/1 (0.00%)",
        "  Dyspnoea 0/1 (0.00%)"
    ]
}